Boehringer Ingelheim Spain

This sponsor has funded 6 studies across 1 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
13754 Finalised Assessment of physical functioning and handling of Spiolto® Respimat® in patients with chronic obstructive pulmonary disease (COPD) requiring... No Yes
19387 Finalised Observational Analysis on the Socio-economic Impact of Idiopathic Pulmonary Fibrosis (IPF) in Spain (OASIS-IPF) No No
19987 Finalised Non-interventional, cross-sectional study to describe NOACs management in patients with non-valvular atrial fibrillation (NVAF) in Spain. RE-CONOCE... No Yes
22940 Finalised Non-interventional, cross-sectional, multicenter study to describe the exacerbations profile of COPD patients Treated with ICS in a real-life primary... No No
29867 Finalised Non-Interventional, cross-sectional study to describe NOACs management in elderly patients with non-valvular atrial fibrillation (NVAF) in Spain.... No No
106524 Planned Observational, multicentre, prospective, real-world post-authorization safety study describing the achievement of nintedanib-associated DIArrhoea... No No

PAS by Risk Management Plan (RMP) requirement

Boehringer Ingelheim Spain

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.